PYC Therapeutics Ltd
ASX:PYC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
PYC Therapeutics Ltd
PP&E Net
PYC Therapeutics Ltd
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
PP&E Net
AU$1.6m
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
31%
|
|
|
Mesoblast Ltd
ASX:MSB
|
PP&E Net
$8.3m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
8%
|
|
|
CSL Ltd
ASX:CSL
|
PP&E Net
$9.3B
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
16%
|
|
|
Race Oncology Ltd
ASX:RAC
|
PP&E Net
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
PP&E Net
AU$6.5m
|
CAGR 3-Years
37%
|
CAGR 5-Years
17%
|
CAGR 10-Years
57%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
PP&E Net
AU$115.6m
|
CAGR 3-Years
83%
|
CAGR 5-Years
89%
|
CAGR 10-Years
N/A
|
|
PYC Therapeutics Ltd
Glance View
PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm has RNA targeted therapeutics design capabilities to deliver technology based on cell penetrating peptides (CPPs). The firm develops a pipeline of therapies, including three preclinical stage programs, which are focused on inherited eye diseases and preclinical discovery efforts, which are focused on neurodegenerative diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate VP-002, which is focused on treating autosomal dominant optic atrophy (ADOA) and PYC-001 drug candidate to treat diabetic retinopathy. Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The firm's discovery and laboratory operations are located in Australia.
See Also
What is PYC Therapeutics Ltd's PP&E Net?
PP&E Net
1.6m
AUD
Based on the financial report for Dec 31, 2025, PYC Therapeutics Ltd's PP&E Net amounts to 1.6m AUD.
What is PYC Therapeutics Ltd's PP&E Net growth rate?
PP&E Net CAGR 10Y
31%
Over the last year, the PP&E Net growth was -24%. The average annual PP&E Net growth rates for PYC Therapeutics Ltd have been 10% over the past three years , 9% over the past five years , and 31% over the past ten years .
